EUROSARC – 9 essais cliniques multicentriques, à l’échelle européenne, pour combattre les cancers rares


Fiche  technique du Projet

• Programme de financement: 7e PCRD – programme Coopération – “Small or medium-scale focused research project”
• Coordinateur: Université Claude Bernard Lyon 1, Prof. Jean-Yves BLAY
• Partenaires :
o Centre Anticancéreux Léon Bérard (FR)
o ACADEMISCH ZIEKENHUIS LEIDEN (NL)
o Institut Gustave Roussy (FR)
o THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (UK)
o FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI (IT)
o ISTITUTO ORTOPEDICO RIZZOLI (IT)
o Institut Bergonié (FR)
o AZIENDA UNITA LOCALE SOCIO SANITARIA N 9 DI TREVISO (IT)
o FUNDACION DE INVESTIGACION DEL CANCER DE LA UNIVERSIDAD DE SALAMANCA (ES)
o MARIA SKLODOWSKA-CURIE MEMORIAL CANCER CENTER (PL)
o RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG (DE)
o SERVEI DE SALUT DE LES ILLES BALEARS (ES)
o EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL (BE)
o Sarcoma Patients Euro Net (DE)
o THE UNIVERSITY OF BIRMINGHAM, OXFORD GENE TECHNOLOGY (OPERATIONS) Ltd (UK)
o Lyon Ingénierie Projets (FR)

• Budget Total: € 7.894.212
• Subvention : € 5.953.832
• Durée : 2011-2016
• Site web : www.eurosarc.eu

Context / Contexte

Sarcomas represent a very heterogenous group of very are malignant tumours, with an overall incidence of 6/100 000 per year. Bone and Soft Tissue sarcomas encompass, according to the most recent WHO classification, more than 50 different rare histotypes and more than 150 molecular subtypes.
Given the rarity of these tumours, it is important and recommended in most clinical practice guidelines to facilitate the participation of these patients in prospective clinical trials. However, even when an accurate diagnosis can be obtained, the next bottleneck to solve for clinical research in rare sarcoma subtypes is the issue of accrual, which may be difficult because of the rarity of these tumours.

Objectives / objectifs

In this perspective the EUROSARC project will develop a reliable, efficient and multinational network of clinical researchers to:
1. Perform the exploration of therapeutic strategies adapted to the histotype and molecular typing of sarcoma in localized phase.
2. Use targeted therapies - guided by the molecular alterations that drive the tumour - in localized phase, in order to allow the implementation of clinical trials which were not previously feasible.
This personalized treatment of sarcoma subtypes represents an important problem which is still unsolved today. This constitutes the rationale for the development of the EUROSARC project which has been designed to develop histotype specific strategies:
1. For histotype-adapted local treatment strategies
2. For the development of a large number and variety of novel targeted therapies directed against oncogenic proteins involved in neoplastic transformation of tumour cells.

Concretely, the EUROSARC project will implement:
• A randomized preoperative radiotherapy trial in retroperitoneal sarcomas (N=1 trial)
• A randomized neoadjuvant cytotoxic chemotherapy trial in localized tumours (N=2 trial)
• 6 trials exploring targeted therapies in rare sarcoma subtypes in prospective randomized trials and in phase II proof of concept studies Biological and clinical material that will be collected in this trial will then be used to perform translational research on these tumours, and to characterize in depth their molecular alterations as well as the effects of drug interventions within the tumours.

Impact / results - Impact / résultats

The EUROSARC project will enable to improve the routine management of these rare tumours by exploring innvative treatment options in neoadjuvant setting and addressing practice-changing clinical research questions which had not been feasible previously. These tasks will be performed by involving patient associations as partners in the project.
In a broader perspective, the EUROSARC project will likely also serve to other pathologies - and the close involvement of patients association all along the trials organisation and implementation process intends to give the European Union researchers a leading role worldwide for the development of novel treatment strategies in academic setting in sarcomas and therefore in rare cancers with the aim of expanding later this consortium worldwide for subsequent trials (especially in Asia and Russia).

 

Rôle de LIP

LIP a accompagné le porteur de projet dans toute la phase de montage : recherche de partenaires, définition des contours du projet, coordination du montage administratif et financier du projet, conseil à la rédaction, proposition d’un modèle de gouvernance, etc. LIP est également partenaire du projet, en charge du management administratif et financier du projet.